Company overview: Salient Pharmaceuticals addresses chronic diarrhea problems with a novel, patent-pending composition of an all-natural compound that has demonstrated signals of efficacy in indications ranging from chemotherapy-induced diarrhea and Clostridium difficile-associated diarrhea to colitis, oral mucositis and radiation exposure. With its first Phase II clinical trial completing in the next 6-9 months, Salient is a unique investment opportunity in the pharmaceutical space.
How TVL helped: The TVL deal team aided in the company’s due diligence process with the Central Texas Angel Network (CTAN). As part of this process, the students conducted research validating the size of Salient’s target markets, found to be smaller than originally thought. Additionally, the TVL team conducted research into the company’s intellectual property and patent prosecution, as well as performed detailed financial analysis on the company’s five-year projections.